Edward Roberts

Dr. Edward Roberts is a medicinal chemist and research scientist who currently serves as the Scientific Advisor at Neumora. Edward has over thirteen years of experience in the pharmaceutical industry, having worked previously as the VP of Preclinical Sciences at BlackThorn Therapeutics and a Research Scientist at Theravance Biopharma, Inc.

Dr. Roberts obtained their undergraduate degree in Chemistry from MIT in 2003. Edward then went on to earn their PhD in Organic Chemistry from Stanford University in 2007. After graduation, they began working at Theravance Biopharma as a Research Scientist, where they designed and synthesized compounds for non-disclosed targets, such as hypertension and asthma. Edward then became the medicinal chemistry lead before leaving the company in 2015 to join BlackThorn Therapeutics as the VP of Preclinical Sciences.

At BlackThorn, Dr. Roberts was the Program Lead for Kappa Opioid Receptor Antagonist Program with a Phase 2 asset in MDD, BTRX-335140. Edward also served as the Head of preclinical toxicology and DMPK/ADME department, overseeing all studies in support of discovery and development programs. In 2020, Neumora acquired BlackThorn, and Dr. Roberts now serves as the Scientific Advisor at Neumora.

Dr. Edward Roberts earned their PhD in Organic Chemistry from UC Irvine and their BS in Chemistry/Biochemistry from the University of North Carolina at Chapel Hill.